Eli Lilly and Co. (LLY) reported its first-quarter results here on Thursday morning and beat estimates for earnings and revenue. The fundamental story may appear strong, but weakness in the broad market averages and fading price momentum may dull the price outlook for the drugmaker's stock.
More from Stocks
Think you can own big tech? You might just get an 'F' for that. Here's what will get you on the other side of this year.
A limited rally cooled some of the negativity on the market, but guess what's going to hit the fan soon?